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Health-related quality of life 
A B S T R A C T   
Introduction: The web-based self-management application Oncokompas was developed to support cancer survi-
vors to monitor health-related quality of life and symptoms (Measure) and to provide tailored information 
(Learn) and supportive care options (Act). In a previously reported randomised controlled trial (RCT), 68% of 
655 recruited survivors were eligible, and of those 45% participated in the RCT. Among participants of the RCT 
that were randomised to the intervention group, 52% used Oncokompas as intended. The aim of this study was to 
explore reasons for not participating in the RCT, and reasons for not using Oncokompas among non-users, and 
the use and evaluation of Oncokompas among users. 
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Methods: Reasons for not participating were assessed with a study-specific questionnaire among 243 survivors 
who declined participation. Usage was investigated among 320 participants randomised to the intervention 
group of the RCT via system data and a study-specific questionnaire that was assessed during the 1 week follow- 
up (T1) assessment. 
Results: Main reasons for not participating were not interested in participation in scientific research (40%) and 
not interested in scientific research and Oncokompas (28%). Main reasons for not being interested in Onco-
kompas were wanting to leave the period of being ill behind (29%), no symptom burden (23%), or lacking 
internet skills (18%). Out of the 320 participants in the intervention group 167 (52%) used Oncokompas as 
intended. Among 72 non-users, main reasons for not using Oncokompas were no symptom burden (32%) or lack 
of time (26%). Among 248 survivors that activated their account, satisfaction and user-friendliness were rated 
with a 7 (scale 0–10). Within 3 (IQR 1–4) sessions, users selected 32 (IQR 6–37) topics. Main reasons for not 
using healthcare options in Act were that the information in Learn was already sufficient (44%) or no supportive 
care needs (32%). 
Discussion: Main reasons for not reaching or using Oncokompas were no symptom burden, no supportive care 
needs, or lack of time. Users selected many cancer-generic and tumour-specific topics to address, indicating 
added value of the wide range of available topics.   
1. Introduction 
Cancer survivors are nowadays expected to manage effects of cancer 
treatment, adopt a healthy lifestyle in order to reduce or prevent late 
effects, and cope with psychological consequences (Greene et al., 2015; 
Howell et al., 2020; Jansen et al., 2015). Self-management of these ef-
fects and navigating through available care options is not just for highly 
motivated cancer survivors, but is becoming necessary for all cancer 
survivors (Howell et al., 2020). Web-based self-management in-
terventions can have positive effects on health-related quality of life 
(HRQOL) and symptom burden in cancer patients (Berry et al., 2014; 
Fridriksdottir et al., 2018; Howell et al., 2017; Skolarus et al., 2019; 
Warrington et al., 2019), and have the advantage that content can be 
tailored to the individual user, and are available at relatively low costs 
(Bashshur et al., 2013; Murray, 2012). However, knowledge is scarce on 
who is reached by such interventions (i.e. who is eligible for such in-
terventions, and who participates in such interventions), and who uses 
those interventions as intended. 
The web-based self-management application Oncokompas was 
developed to support cancer survivors in self-management, and contains 
three components: 1) measure: monitoring health-related quality of life 
and cancer-generic and tumour-specific symptoms by means of patient- 
reported outcome measures (PROMs), 2) learn: providing tailored in-
formation based on PROM scores, and 3) act: providing a personalized 
overview with recommended supportive care options (van der Hout 
et al., 2017). A randomised controlled trial (RCT) showed that Onco-
kompas is effective to reduce symptoms and improve HRQOL in cancer 
survivors (van der Hout et al., 2020b), and is not more expensive than 
usual cancer survivorship (van der Hout et al., 2020a). These are 
important conditions in order to implement Oncokompas in routine 
cancer survivorship care. However, to tailor implementation strategies it 
is also important to know which cancer survivors are reached and rea-
sons why people are not reached, and to evaluate the actual usage of 
Oncokompas and reasons why cancer survivors are not using 
Oncokompas. 
In our previous report, we investigated the reach by assessing the 
eligibility rate and participation rate, in the context of an RCT on the 
efficacy and cost-utility of Oncokompas (van der Hout et al., 2020b, 
2020a, 2017). We found that 68% of the respondents were eligible to use 
Oncokompas (they had access to the internet and an e-mail address), of 
whom 45% agreed to participate in the RCT on Oncokompas. Factors 
associated with eligibility were male sex, younger age, higher health 
literacy, higher positive adjustment to cancer, no unmet needs regarding 
health system information and supportive care, and tumour type. Fac-
tors associated with participation were a medium and higher education 
level, unmet supportive care needs for sexual problems, and a higher 
belief of control of health by powerful others (van der Hout et al., 
2020b). However, specific reasons why eligible people decided not to 
participate in this RCT are not known. As there is evidence on reasons 
why cancer survivors decline participation in clinical trials (Jenkins and 
Fallowfield, 2000; Mills et al., 2006; Naidoo et al., 2020; Viljoen et al., 
2020), we focussed on reasons why eligible survivors were not inter-
ested in web-based self-management applications. 
It is known that eHealth applications are not always used as intended 
(Kelders et al., 2012; Sieverink et al., 2017b). eHealth literacy and 
internet skills are important factors in using eHealth interventions as 
intended by the developers, and to profit from eHealth interventions 
(Halwas et al., 2017). Initial results on the usage of Oncokompas showed 
that 52% of the users, used Oncokompas as intended (van der Hout et al., 
2020b). Usage as intended was defined as the minimal use that was 
expected to improve outcomes, and was defined as completing at least 
the components Measure and Learn for at least one topic. Factors that 
were found to be associated with usage as intended were a higher ed-
ucation level, having a partner, and not being employed (van der Hout 
et al., 2020b). Reasons for not using Oncokompas among those who did 
not use Oncokompas, as well as the evaluation of Oncokompas among 
users may provide more insight into how to improve usage of web-based 
self-management interventions. 
The aim of this study was to investigate the usage of Oncokompas, by 
investigating reasons for not using Oncokompas, and to investigate 
system data and evaluate Oncokompas among users. The results are 
important in the continuous cycle of improvement and updating the 
content and design of web-based self-management interventions (Cat-
well and Sheikh, 2009; Granja et al., 2018). 
2. Methods 
2.1. Study design 
The study was conducted in the context of an RCT on efficacy and 
cost-utility of Oncokompas. Details of the study procedures are 
described elsewhere (van der Hout et al., 2020b, 2017). To investigate 
the reach, a two-step inclusion method was used: a survey on supportive 
cancer care (part 1), and the actual RCT (part 2). Respondents of the 
survey were invited to participate in the RCT if they were eligible to use 
Oncokompas. They were eligible when they had internet access and an 
e-mail address (subsample 1). Via this two-step inclusion method asso-
ciations of eligibility and participation could be investigated, because 
information on non-eligible survivors and non-participants was avail-
able from the survey. The study protocol was approved by the Medical 
Ethics Committee of the VU University Medical Center (2015.523), 
published previously (van der Hout et al., 2017), and registered in the 
Netherlands Trial Register (NTR5774). All participants provided (on-
line) written informed consent. 
Cancer survivors were invited via this two-step inclusion method 
from October 2016 until July 2017 by a letter from their (former) 
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treating physician. From July 2017 to May 2018, 1462 cancer survivors 
were invited to participate directly. In total, 625 survivors participated 
in the RCT, of whom 320 were randomised into the intervention group, 
and had access to Oncokompas (subsample 2). 
To investigate the usage of Oncokompas, system data was extracted 
from RCT participants randomised into the intervention group, who had 
access to Oncokompas (subsample 2). To evaluate the usage of Onco-
kompas, data from the first follow-up assessment in the RCT was used. 
The link to the follow-up assessment was sent by mail, 1 week after 
Oncokompas was used as intended. If Oncokompas was not used, the 
link was sent 2 weeks after randomisation. 
2.2. In- and exclusion criteria 
The inclusion criteria for the survey (part 1) were: being diagnosed 
with breast cancer, colorectal cancer, head and neck cancer or lym-
phoma; being ≥18 years, and having completed treatment with curative 
intent 3 months to 5 years ago (all treatment modalities). Cancer sur-
vivors who had not yet completed endocrine therapy or immunotherapy 
were included 3 months to 5 years after their previous treatment, and 
patients diagnosed with lymphoma who had a wait-and-see regimen, 
were included 3 months to 5 years after the date of diagnosis. The 
exclusion criteria for part 1 were: male cancer survivors diagnosed with 
breast cancer, severe cognitive impairment, insufficient mastery of the 
Dutch language, or physical inability to complete a questionnaire (e.g. 
blind, or paralyzed). Additional eligibility criteria for the RCT (part 2) 
were: having access to the internet and having an e-mail address. 
2.3. Intervention 
A detailed description of Oncokompas has been published previously 
(van der Hout et al., 2020b, 2017). In short, Oncokompas is an eHealth 
self-management application that supports cancer survivors to monitor 
their HRQOL and cancer-generic and tumour-specific symptoms. 
Oncokompas includes 32 topics in 5 cancer-generic domains: physical, 
psychological and social functioning, lifestyle, and existential issues. In 
addition, tumour-specific modules are available targeting head and neck 
cancer (6 topics), colorectal cancer (8 topics), breast cancer (9 topics) 
and (non-)Hodgkin lymphoma survivors (7 topics). Oncokompas con-
sists of three components: ‘Measure’, ‘Learn’, and ‘Act’. In the ‘Measure’ 
component, cancer survivors complete PROMs on the topic(s) of choice. 
Data from the ‘Measure’ component are processed in real-time and 
linked to feedback in the ‘Learn’ component. In the ‘Learn’ component 
feedback is provided by means of a 3-colour system: green (no elevated 
well-being risks), orange (elevated well-being risks), and red (seriously 
elevated well-being risks). Cancer survivors receive personalized infor-
mation on the outcomes (Learn, information), and comprehensive self- 
care advice (Learn, advice). In the ‘Act’ component, cancer survivors 
obtain a personalized overview with supportive care options. If a user 
has elevated well-being risks (orange score), the feedback includes 
suggestions for self-help interventions, and if a user has seriously 
elevated well-being risks, the feedback includes suggestions for medical 
specialists or their general practitioner (van der Hout et al., 2020b, 
2017). 
2.4. Outcome measures 
2.4.1. Reasons for not participating 
Among eligible cancer survivors who were not willing to participate 
in the RCT (subsample 1), reasons for not participating were assessed in 
an online form with response options: ‘not interested in Oncokompas’, 
‘not interested in scientific research’, ‘not interested in Oncokompas and 
scientific research’, and ‘other reasons’. Reasons for not being interested 
in Oncokompas were further explored with pre-set response options, and 
multiple reasons were allowed. In case the online form was not 
completed, but the reason for not participating was indicated by phone 
or e-mail, the reasons were categorized into one of the categories 
manually. 
2.4.2. Reasons for not using Oncokompas 
Among all participants of the RCT, who were randomised to the 
intervention group (access to Oncokompas), but who did not use 
Oncokompas, reasons for not using Oncokompas were explored with 
pre-set response options in the first follow-up (T1) assessment of the RCT 
(1 week after usage of Oncokompas, with a maximum of 2 weeks after 
randomisation). 
2.4.3. Usage of Oncokompas 
Usage was evaluated among those who were randomised into the 
intervention group in the RCT (subsample 2), and reported previously 
(van der Hout et al., 2020b). Usage was investigated via system data 
from Oncokompas and data from an evaluation questionnaire. System 
data was extracted separately for each component of Oncokompas 
(Measure, Learn and Act). For the component Measure: number of 
completed topics per user, and number of completions per topic; for the 
component Learn: number of green (no elevated well-being risk), orange 
(elevated well-being risk) and red scores (seriously elevated well-being 
risk) per user, and the number of green, orange, and red scores per topic, 
and for the component Act: number of clicks to supportive care options. 
Usage as intended was defined as the completion of the components 
Measure and Learn for at least one topic, at least once during the 6- 
month follow-up period. Based on expert opinion of our team, with 
experience from clinical practice, together with directions from litera-
ture, it was expected that using at least these two components are 
needed to improve outcomes. Studies have shown that PROMs can be 
used for screening to identify symptoms, and can be used to track 
changes over time (Duman-Lubberding et al., 2017; Snyder et al., 2011; 
Velikova et al., 2008). Clinical experience suggest that completing 
PROMs is already beneficial for cancer survivors, but evidence is lacking 
(Coyne, 2013; Palmer et al., 2011), and therefore, the information in the 
component Learn is thought to be needed for an actual beneficial effect. 
The component Act is possibly not needed for each user, as the infor-
mation and self-care advice can already be sufficient to improve the 
outcomes. The usage rate was calculated as the number of users who 
used Oncokompas as intended, divided by the total number of users. 
In the T1 assessment, participants were invited to complete the 
study-specific evaluation questionnaire. Satisfaction and user- 
friendliness were evaluated via items on an 11-point rating scale 
(0− 10). User experiences and satisfaction on several aspects of the 
components Measure, Learn and Act were evaluated via multiple-choice 
questions. 
2.5. Statistical analyses 
Descriptive statistics were generated to characterize the study sam-
ple (by means of frequency and percentage for categorical data and 
median and interquartile range (IQR) for continuous data), calculate the 
eligibility, participation and usage rates and describe the reasons for not 
participating and not using Oncokompas, and system data. Statistical 
analyses were performed using IBM SPSS Statistics version 26 (IBM 
Corp., Armonk, NY, USA). 
3. Results 
The flow chart of the study is shown in Fig. 1. Characteristics of the 
study population are shown in Table 1. 
3.1. Reasons for not participating 
Of the 444 eligible cancer survivors invited to participate in the RCT 
on Oncokompas (subsample 1), 201 agreed to participate (participation 
rate: 45%). 
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Of the 243 eligible survivors that declined participation, 152 (63%) 
responded and actively declined, and 91 (37%) did not respond. Among 
those who responded, reasons for not participating were they were not 
interested in participation in scientific research (n = 61, 40%), they were 
not interested in participation in scientific research and not interested in 
Oncokompas (n = 42, 28%), they were not interested in Oncokompas (n 
= 28, 18%), they did not want to participate because of personal reasons 
(n = 13, 9%), or they did not want to provide reasons (n = 8, 5%). 
In total, 70 (29%) indicated that they were not interested in Onco-
kompas. Reasons for not being interested in Oncokompas (n = 70) was 
that someone wanted to leave the period of being ill behind (n = 20, 
29%), did not experience any symptom burden (n = 18, 23%), thought 
they would lack sufficient internet skills (n = 14, 18%) no need for 
supportive care (n = 11, 14%), Oncokompas does not fit to their per-
sonal situation (n = 10, 13%), no time/motivation (n = 8, 11%), too 
confronting (n = 8, 11%), no need for information and advice (n = 7, 
9%). No one indicated that the aim of Oncokompas was unclear (n = 0, 
0%). 
3.2. Reasons for not using Oncokompas 
Among the 320 participants (subsample 2) who were randomised to 
the intervention group, 72 (23%) did not activate their account. Among 
them, 31 (43%) completed the first assessment of the RCT, two weeks 
after being provided access to Oncokompas. Among them, reasons for 
not using Oncokompas were no symptom burden (n = 10, 32%), lack of 
time (n = 8, 26%), not interested (n = 3, 10%), not fitting to personal 
problems (n = 3, 10%), personal reasons (n = 3, 10%), login details lost 
or not received (n = 3, 10%), forgotten to activate Oncokompas account 
(n = 2, 6%), aim of Oncokompas was not clear (n = 2, 6%), too difficult 
(n = 1, 3%), too comprehensive (n = 1, 3%), technical problems (n = 1, 
3%). No one indicated that it was too confronting. 
3.3. Usage of Oncokompas 
Among the 320 participants (subsample 2) who were randomised to 
the intervention group, 248 (78%) activated their account, and 167 
(52%) used Oncokompas as intended (usage rate: 52%) (van der Hout 
et al., 2020b). The flow chart of the usage, with the completion per 
subsequent component is shown in Fig. 2. 
During the 6-months follow-up period of the RCT, the median 
number of logins in Oncokompas was 3 (IQR 1–4) among the 248 who 
activated their account, and 3 (IQR 2–5) among the 167 who used 
Oncokompas as intended. 
Fig. 1. Flow chart of the study.  
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Among the 248 participants who activated their Oncokompas ac-
count, 217 (88%) completed the first follow-up assessment (one week 
after using Oncokompas for the first time). The median score on satis-
faction was 7 (IQR 6–8), and on user-friendliness 7 (IQR 5–8). The 
median score on the question ‘How likely is it that you will recommend 
Oncokompas to other cancer survivors’ was 6 (IQR 5–7). Self-reported 
time spent in Oncokompas was less than 30 min as reported by 28%, 
between 30 and 60 min by 48%, and more than 60 min by 23% of the 
users. The time it took to complete Oncokompas was evaluated as ‘way 
too long’ by 6%, ‘too long’ by 25%, ‘exactly right’ by 66%, and ‘too 
short’ by 3% of the users. A minority (15%) indicated that they had help 
of others (e.g. partner) using Oncokompas, and none of the participants 
reported that they e-mailed or called the helpdesk of Oncokompas. Most 
users (75%) intended to login to Oncokompas again and read the in-
formation and advice, and supportive care options once again. Most 
users (71%) indicated that they wanted to use Oncokompas again. 
3.3.1. Measure 
In total, 201 participants (81% of those who activated their account) 
completed the component Measure for at least 1 topic (Fig. 2), during 
the 6-months follow-up period. The median number of topics completed 
per person was 32 (IQR: 6–37). The cancer-generic topics that were 
chosen most often were: fatigue, sleep, and daily functioning, all from 
the physical quality of life domain (Fig. 3). 
The number of questions in the Measure component was rated as ‘not 
feasible’ by 6%, ‘a little feasible’ by 41%, ‘feasible’ by 41%, and ‘very 
feasible’ by 9%. The overlap between questions in Measure was rated as 
‘not’ by 16%, ‘a little’ by 57%, ‘much’ by 24%, and ‘very much’ by 3%. 
3.3.2. Learn 
In total, 167 users (83% of those who completed the Measure 
component) read the page with information for at least 1 topic. Of them, 
140 users (84% of those who read the information page) also read the 
page with advice and self-help tips for at least 1 topic. In total, 4497 
topics were completed, on which 73% of the users had a green score, 
18% had an orange score, and 9% had a red score. Per user, the median 
number of green scores was 21 (IQR 2–28), the median number of or-
ange scores was 4 (IQR: 2–8), and the median number of red topics was 2 
(IQR: 0–4). The scores on cancer-generic topics are shown in Fig. 3 and 
the scores on tumour-specific topics are shown in Fig. 4. 
Table 1 
Baseline characteristics of cancer survivors analysed for the reach and usage.  




RCT (n = 243) 
Participants of 







Age (years) 65 (57–71) 64 (56–70) 65 
(55–72) 
65 (57–70) 
Sex (female) 148 (61%) 120 (60%) 73 (48%) 85 (51%) 
Marital status 
(partner) 
193 (79%) 174 (87%) 120 
(78%) 
144 (86%) 
Education level     
Low 110 (46%) 67 (33%) 59 (39%) 52 (31%) 
Medium 64 (26%) 71 (35%) 54 (35%) 51 (31%) 




75 (31%) 69 (34%) 66 (43%) 56 (34%) 
Tumour type     
Breast cancer 88 (36%) 82 (41%) 35 (23%) 31 (19%) 
Colorectal 
cancer 
73 (30%) 61 (30%) 41 (27%) 39 (23%) 
Head and neck 
cancer 
45 (19%) 34 (17%) 40 (26%) 59 (35%) 
Lymphoma 37 (15%) 24 (12%) 37 (24%) 38 (23%) 
Tumour stage     
Stage I 73 (30%) 77 (38%) 52 (34%) 54 (32%) 
Stage II 64 (26%) 44 (22%) 31 (20%) 42 (25%) 
Stage III 53 (22%) 40 (20%) 28 (18%) 33 (20%) 
Stage IV 28 (12%) 26 (13%) 32 (21%) 32 (20%) 
Unknown 25 (10%) 14 (7%) 10 (7%) 6 (4%) 
Time since 
diagnosis     
3-<12 months 29 (12%) 22 (11%) 23 (15%) 16 (10%) 
12-<24 
months 
90 (37%) 66 (33%) 50 (33%) 54 (32%) 
24-60 months 124 (51%) 113 (56%) 80 (52%) 97 (58%) 
Treatment type 
(multimodal) 
154 (64%) 140 (70%) 90 (60%) 93 (56%) 
Comorbidities 
(multiple) 
55 (23%) 48 (24%) 37 (24%) 34 (20%)  
a Median (IQR), or n (%). 
Fig. 2. Flow chart of usage of Oncokompas. 
* for at least 1 topic. 
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Fig. 3. Number of completions per cancer-generic topic within Oncokompas, and corresponding scores, based on system data. * on these topics users can only score 
green or orange. 
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Fig. 4. Number of completions per tumour-specific topic within Oncokompas, and corresponding scores, based on system data. * on these topics users can only score 
green or orange. 
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The question ‘Did the score correspond with your personal experi-
ence?’ was answered as ‘not corresponding’ by 7%, ‘little correspond-
ing’ by 43%, ‘much corresponding’ by 45%, and ‘very much 
corresponding’ by 5% of the users. Most users (74%) rated the scores as 
clear and understandable. The information accompanying the scores 
was rated by most users as clear (72%), complete (63%), and useful 
(53%). Of the users, 61% indicated that the provided information and 
advice in the Learn component did not fit their personal situation, 57% 
that it not fit their health status, and 35% indicated that the information 
had added value for them. Slightly more than half (52%) of the users 
indicated that they received sufficient information to cope with their 
problem. 
3.3.3. Act 
In total, 80 users (57% of those who completed the Learn compo-
nent) completed the Act component for at least 1 topic (Fig. 2). The 
number of proposed supportive care options was rated as ‘too little’ by 
13%, ‘exactly right’ by 66%, and ‘too much’ by 21% of the users. 
Nineteen percent of the users indicated that they had already used 
supportive care options suggested by Oncokompas after 1-week follow- 
up, and 41% of the users indicated that they wanted to use the proposed 
supportive care options in the near future. 
Seventy-two users indicated that they did not want to use the pro-
posed supportive care options in the Act component. Reasons were that 
the information and advice provided in Oncokompas was already suf-
ficient (n = 32, 44%), they were not interested or did not have a need for 
the supportive care option (n = 23, 32%), they were already using the 
supportive care option (n = 10, 14%), they used the supportive care 
option before (n = 9, 13%), they were limited in functioning, therefore 
using supportive care options was not possible (n = 6, 8%), a lack of time 
(n = 5, 7%), there was too little information on the supportive care 
option available (n = 3, 4%). No one indicated that the supportive care 
option was not available or had a wait-list, the supportive care option 
was too far away, or the supportive care option was too expensive and/ 
or was not reimbursed. 
4. Discussion 
In this study, we investigated reasons for not reaching or not using 
the web-based self-management application Oncokompas among cancer 
survivors, and evaluated Oncokompas among users. Half of the eligible 
cancer survivors did not want to participate in the RCT investigating 
Oncokompas. The most often indicated reason for not participating in 
the RCT was that cancer survivors did not want to participate in scien-
tific research (40%), followed by that they did not want to participate in 
scientific research and were not interested in Oncokompas (28%), and 
were not interested in Oncokompas (18%). Main reasons for not being 
interested in Oncokompas were that cancer survivors wanted to leave 
the period of being ill behind, did not experience symptom burden, 
thought they would lack sufficient internet skills, or they did not have a 
need for supportive care. The main reason for not using Oncokompas 
among RCT participants was that no symptom burden was experienced. 
Among breast cancer survivors, the RCT participation rate was 
highest, but actual Oncokompas usage rate was lowest compared to the 
other tumour types. It might be that breast cancer survivors are willing 
to participate in scientific research, but that they are performing rela-
tively well, and therefore did not use Oncokompas as often. In contrast, 
head and neck cancer survivors were participating less frequently in the 
RCT, but if they did, they used Oncokompas more often, possibly 
because they were suffering from symptoms more often. This corre-
sponds with the percentage of seriously elevated well-being risks on 
tumour-specific symptoms, which was lowest among breast cancer 
survivors (5% of completed tumour-specific topics), and highest among 
head and neck cancer survivors (18% of completed tumour-specific 
topics). 
While reasons such as no symptom burden or no supportive care 
needs are legitimate reasons for not participating or using Oncokompas, 
other reasons mentioned might be useful to improve (access to) web- 
based interventions. These include no time, not fitting to personal sit-
uation and that people think they lack skills to use such an intervention. 
These reasons emphasize the need for easy to use applications, with 
simple login procedures, which do not take much time to use. Tailoring 
evidence-based information to the individual cancer survivor is seen as 
an advantage of Oncokompas, as this makes the information applicable 
to the users’ situation and needs, and can be directly applied (Murray, 
2012). However, further tailoring might improve Oncokompas, as more 
than half of the users indicated that the information did not match with 
their personal situation and health status, and one third of the users 
indicated that it took too much time to complete Oncokompas. 
The number of topics that users chose to address during 6-months 
follow-up was high (median of 32 topics, during a median of 3 ses-
sions). This may explain why one third of the users rated the time it took 
to complete Oncokompas as too long. Encouraging users to address one 
or two topics at a time, that are the most important for them, and 
stimulate repeated use to cover multiple topics is recommended to 
improve usage as intended. Users were burdened by many different 
cancer generic, as well as tumour-specific symptoms, which is in line 
with studies on symptoms that cancer survivors can experience (Aar-
onson et al., 2014; Given and Given, 2013; Harrington et al., 2010; 
Rowland and Bellizzi, 2014). Furthermore, symptoms should be seen as 
a cluster of interrelated symptoms, and not seen as isolated symptoms 
(Aaronson et al., 2014). Therefore the range of topics within web-based 
self-management interventions should be wide, and not focussed on only 
one topic. 
Multimedia tools such as podcasts, videos, infographics and gamifi-
cations elements may also increase usage and stimulate repeated use 
(Araújo-Soares et al., 2019; Kelders et al., 2013; Moore et al., 2019; 
Perski et al., 2017; Sardi et al., 2017; Sieverink et al., 2017b). Moreover, 
instructions for healthcare professionals on how to recommend Onco-
kompas to cancer survivors might increase the reach. 
Users had no elevated well-being risks on 73% of the topics they 
completed and had (seriously) elevated well-being risks on 27% of the 
topics. The cancer-generic topics that were most often selected were 
fatigue, sleep, and daily functioning, all from the physical quality of life 
domain. Topics with the highest percentage of seriously elevated well- 
being risk (red score) were daily functioning, psychological problems, 
work, and sexuality, which are symptoms often observed among cancer 
survivors (Aaronson et al., 2014; Eeltink et al., 2021; Foster et al., 2009; 
Harden et al., 2015; Stein et al., 2008). Whereas some other web-based 
self-management interventions target a single topic, or a limited amount 
of topics (Foster et al., 2016; Kim and Park, 2015; Willems et al., 2015), 
we think that the variety of topics that are incorporated in Oncokompas 
is valuable in self-management of HRQOL and symptoms, because of the 
wide range of symptoms that cancer survivors can experience (Aaronson 
et al., 2014; Given and Given, 2013; Lagergren et al., 2019; Stein et al., 
2008). A previous qualitative study among head and neck cancer pa-
tients showed that some participants had doubts about the added value 
of Oncokompas, but they mentioned it would be helpful when symptoms 
are present (Duman-Lubberding, 2018) When there is a wide range of 
available topics, there is more chance that it is applicable to the users 
situation. 
It was found that after each step of Oncokompas (Measure, Learn, 
Act), some users were not going to the next step. After activation of the 
account 19% did not go to the Measure component, 17% of them did not 
go to the Learn component with information, 16% of them did not go the 
Learn component with advice, and 43% of them did not go to the Act 
component. About half of the users indicated that the information and 
advice provided in the component Learn was already sufficient to cope 
with their problem, and therefore, the component Act might not be 
necessary for all users. Oncokompas is a complex intervention, with 
multiple components, domains and topics, and every cancer survivor has 
other preferences and needs. Therefore, it is difficult to measure the 
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dose-response relation of usage, and determine the accurate cut-off 
point when it is used as intended (Murray, 2012; Sieverink et al., 
2017a). In this study, we used the definition of used as intended when 
the components Measure and Learn were completed for at least one 
topic. Only 52% of the participants met the defined criteria, which is 
similar to other studies, showing that about 50% of the participants fully 
adhere to web-based interventions (Kelders et al., 2012). Reasons for 
non-use were similar to those of a scoping review on non-using digital 
patient-reported outcome interventions, that reasons were related to 
skills, emotional distress and technical barriers (Nielsen et al., 2020). 
Among users, Oncokompas was evaluated positively and most users 
indicated that they wanted to use Oncokompas again. In contrast, only 
35% of the cancer survivors reported that the information had added 
value for them, and the question whether they would recommend 
Oncokompas to other cancer survivors was rated with a median of 6. 
This seems contradictory to the 71% of users that indicated that they 
want to use Oncokompas again. This might suggest that knowing that 
support is available when needed, or when symptoms are present is 
already sufficient. Further research into usage patterns is needed to gain 
insight into which specific components and topics contribute to the 
intervention effect of Oncokompas, and to be able to predict which user 
needs which components (Jonkman et al., 2016). Usage patterns would 
be helpful to gain insight into ways to improve usage (Kelders and Van 
Gemert-Pijnen, 2013). 
A limitation of this study is that we used ‘willing to participate in an 
RCT on Oncokompas’ as a proxy for ‘being interested in Oncokompas’, 
while these measures might not correspond in practice. Most of the non- 
participants indicated they were not interested in participation in sci-
entific research (40%), but there is also a considerable number of non- 
participants that indicated they were both not interested in scientific 
research and in Oncokompas (28%). Unfortunately, no additional 
(qualitative) data is available to know which was the main reason for 
declining participating in the RCT. Often mentioned reasons for 
declining participation in clinical cancer trials, e.g. in medication trials, 
are that cancer patients did not want to get randomised, did not want to 
get a placebo, or fear related to the clinical trial (Jenkins and Fallow-
field, 2000; Mills et al., 2006; Naidoo et al., 2020; Viljoen et al., 2020). It 
could be questioned whether these reasons are similar for declining 
participation in RCTs on eHealth interventions, as these interventions 
are relatively low intensive. Reasons for declining participation in trials 
with those types of interventions might be that they lack skills, are un-
able to engage with those interventions or did not perceive a need for it 
(Foster et al., 2015). Another limitation is that the findings reported per 
tumour type are based on relatively small study samples. Further 
research on real-world data, and qualitative research is necessary to 
extend our knowledge on the usage of web-based self-management ap-
plications as Oncokompas. The scientific context in which Oncokompas 
was offered to cancer survivors, might have led to selection bias, and the 
results might have been different when offered in routine care. We found 
that the scientific context plays a role in the decision not to participate in 
web-based self-management interventions, as this was the main reason 
for not participating. When Oncokompas was offered directly to cancer 
survivors, the response rate was lower than the response rate of the 
survey of supportive care (step 1) (29% vs. 44%). Furthermore, re-
spondents of the survey were older and had a shorter time since diag-
nosis than non-respondents of the survey, but there were no differences 
regarding sex, tumour type, or tumour stage (van der Hout et al., 
2020b). However, due to ethical and practical reasons, we think this was 
the best method to investigate the reach of Oncokompas. 
In conclusion, reasons for not reaching or using Oncokompas were no 
symptom burden, no need for supportive care, or lack of time. The main 
lessons learned are that eHealth applications aiming to support cancer 
survivors to improve their quality of life and reduce symptoms, should 
encompass a large variety of topics that users can choose from, and that 
survivors seem most burdened by tumour-specific symptoms and 
therefore these topics should definitely be included. In order to improve 
the reach and use of web-based self-management interventions, they 
should be easy to with simple login procedures, which do not take much 
time to use. 
Funding 
This work was supported by the Dutch Cancer Society (KWF Kan-
kerbestrijding) (grant number VU 2014-7202). 
Declaration of competing interest 
IMV-dL has received grants from the Dutch Cancer Society (KWF 
Kankerbestrijding), Pink Ribbon, the Netherlands Organization for 
Health Research and Development (ZonMW), the SAG Founda-
tion–Zilveren Kruis Health Care Assurance Company, Danone Eco-
fund–Nutricia, Red-kite (distributor of eHealth tools), and Bristol-Myers 
Squibb, during the conduct of this study. CRL has received personal fees 
for global advisory board participation from MSD, during the conduct of 
this study. All other authors have no conflicts of interest. 
References 
Aaronson, N.K., Mattioli, V., Minton, O., Weis, J., Johansen, C., Dalton, S.O., Verdonck- 
de Leeuw, I.M., Stein, K.D., Alfano, C.M., Mehnert, A., de Boer, A., van de Poll- 
Franse, L.V., 2014. Beyond treatment - psychosocial and behavioural issues in cancer 
survivorship research and practice. Eur. J. Cancer Suppl. 12, 54–64. https://doi.org/ 
10.1016/j.ejcsup.2014.03.005. 
Araújo-Soares, V., Hankonen, N., Presseau, J., Rodrigues, A., Sniehotta, F.F., 2019. 
Developing behavior change interventions for self-management in chronic illness: an 
integrative overview. Eur. Psychol. https://doi.org/10.1027/1016-9040/a000330. 
Bashshur, R.L., Shannon, G., Krupinski, E.A., Grigsby, J., 2013. Sustaining and realizing 
the promise of telemedicine. Telemed. e-Health 19, 339–345. https://doi.org/ 
10.1089/tmj.2012.0282. 
Berry, D.L., Hong, F., Halpenny, B., Partridge, A.H., Fann, J.R., Wolpin, S., Lober, W.B., 
Bush, N.E., Parvathaneni, U., Back, A.L., Amtmann, D., Ford, R., 2014. Electronic 
self-report assessment for cancer and self-care support: results of a multicenter 
randomized trial. J. Clin. Oncol. 32, 199–205. https://doi.org/10.1200/ 
JCO.2013.48.6662. 
Catwell, L., Sheikh, A., 2009. Evaluating eHealth interventions: the need for continuous 
systemic evaluation. PLoS Med. 6, e1000126 https://doi.org/10.1371/journal. 
pmed.1000126. 
Coyne, J.C., 2013. Benefits of screening cancer patients for distress still not 
demonstrated. Br. J. Cancer. https://doi.org/10.1038/bjc.2013.16. 
Duman-Lubberding, S., 2018. Online Patient Reported Outcome Measures to Facilitate 
Supportive Care in Head and Neck Cancer Patients. 
Duman-Lubberding, S., van Uden-Kraan, C.F., Jansen, F., Witte, B.I., Eerenstein, S.E.J., 
van Weert, S., de Bree, R., Leemans, C.R., Verdonck-de Leeuw, I.M., 2017. Durable 
usage of patient-reported outcome measures in clinical practice to monitor health- 
related quality of life in head and neck cancer patients. Support Care Cancer 25, 
3775–3783. https://doi.org/10.1007/s00520-017-3808-3. 
Eeltink, C.M., Rood, J.A.J., Nauta, I.H., Lissenberg-Witte, B.I., Incrocci, L., Visser, O., 
Verdonck-de Leeuw, I.M., Zweegman, S., 2021. Reply to: “discussing sexuality in 
cancer care: towards personalized information for cancer patients and survivors.”. 
Support Care Cancer. https://doi.org/10.1007/s00520-020-05625-4. 
Foster, C., Wright, D., Hill, H., Hopkinson, J., Roffe, L., 2009. Psychosocial implications 
of living 5 years or more following a cancer diagnosis: a systematic review of the 
research evidence. Eur. J. Cancer Care 18, 223–247. https://doi.org/10.1111/ 
j.1365-2354.2008.01001.x. 
Foster, A., Horspool, K.A., Edwards, L., Thomas, C.L., Salisbury, C., Montgomery, A.A., 
O’Cathain, A., 2015. Who does not participate in telehealth trials and why? A cross- 
sectional survey. Trials 16, 1–10. https://doi.org/10.1186/s13063-015-0773-3. 
Foster, C., Grimmett, C., May, C.M., Ewings, S., Myall, M., Hulme, C., Smith, P.W., 
Powers, C., Calman, L., Armes, J., Breckons, M., Corner, J., Fenlon, D., Batehup, L., 
Lennan, E., Morris, C., Neylon, A., Ream, E., Turner, L., Yardley, L., Richardson, A., 
May, C.R., 2016. A web-based intervention (RESTORE) to support self-management 
of cancer-related fatigue following primary cancer treatment: a multi-centre proof of 
concept randomised controlled trial. Support Care Cancer 24, 2445–2453. https:// 
doi.org/10.1007/s00520-015-3044-7. 
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